Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 8:7:598846.
doi: 10.3389/fcvm.2020.598846. eCollection 2020.

Prevalence of Venous Thromboembolism in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis

Mouhand F H Mohamed  1 , Shaikha D Al-Shokri  1 , Khaled M Shunnar  1 , Sara F Mohamed  1 , Mostafa S Najim  1 , Shahd I Ibrahim  1 , Hazem Elewa  2 , Lina O Abdalla  1 , Ahmed El-Bardissy  3 , Mohamed Nabil Elshafei  3 , Ibrahim Y Abubeker  4 , Mohammed Danjuma  1   5 , Khalid M Dousa  6 , Mohamed A Yassin  7
Affiliations

Prevalence of Venous Thromboembolism in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis

Mouhand F H Mohamed et al. Front Cardiovasc Med. .

Abstract

Background: Recent studies revealed a high prevalence of venous thromboembolism (VTE) events in coronavirus disease 2019 (COVID-19) patients, especially in those who are critically ill. Available studies report varying prevalence rates. Hence, the exact prevalence remains uncertain. Moreover, there is an ongoing debate regarding the appropriate dosage of thromboprophylaxis. Methods: We performed a systematic review and proportion meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched PubMed and EMBASE for studies exploring the prevalence of VTE in critically ill COVID-19 patients till 25/07/2020. We pooled the proportion of VTE. Additionally, in a subgroup analysis, we pooled VTE events detected by systematic screening. Finally, in an exploratory analysis, we compared the odds of VTE in patients on prophylactic compared with therapeutic anticoagulation. Results: The review comprised 24 studies and over 2,500 patients. The pooled proportion of VTE prevalence was 0.31 [95% confidence interval (CI) 0.24, 0.39; I 2 94%], of VTE utilizing systematic screening was 0.48 (95% CI 0.33, 0.63; I 2 91%), of deep venous thrombosis was 0.23 (95% CI 0.14, 0.32; I 2 96%), and of pulmonary embolism was 0.14 (95% CI 0.09, 0.20; I 2 90%). Exploratory analysis of few studies, utilizing systematic screening, VTE risk increased significantly with prophylactic, compared with therapeutic anticoagulation [odds ratio (OR) 5.45; 95% CI 1.90, 15.57; I 2 0%]. Discussion: Our review revealed a high prevalence of VTE in critically ill COVID-19 patients. Almost 50% of patients had VTE detected by systematic screening. Higher thromboprophylaxis dosages may reduce VTE burden in this patient's cohort compared with standard prophylactic anticoagulation; however, this is to be ascertained by ongoing randomized controlled trials.

Keywords: COVID-19; DVT—deep vein thrombosis; ICU; SARS-CoV-2; VTE; thrombosis; venous.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
Forest plot showing the overall pooled proportion of VTE events.
Figure 3
Figure 3
Forest plot showing the pooled proportion of VTE events utilizing systematic screening methods.
Figure 4
Figure 4
Forest plot showing the pooled proportion of VTE events utilizing non-systematic screening methods.
Figure 5
Figure 5
Forest plot showing the overall pooled proportion of DVT.
Figure 6
Figure 6
Forest plot showing the overall pooled proportion of PE.
Figure 7
Figure 7
Forest plot showing the VTE event odds in the prophylactic anticoagulation group, compared with therapeutic dosing.
See this image and copyright information in PMC

References

    1. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. (2020) 191:145–7. 10.1016/j.thromres.2020.04.013 - DOI - PMC - PubMed
    1. McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. (2020) 127:571–87. 10.1161/circresaha.120.317447 - DOI - PMC - PubMed
    1. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. . ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. (2020) 18:1023–6. 10.1111/jth.14810 - DOI - PMC - PubMed
    1. Llitjos JF, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. (2020) 18:1743–6. 10.1111/jth.14869 - DOI - PMC - PubMed
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. (2009) 339:332–6. 10.1136/bmj.b2535 - DOI - PMC - PubMed

Publication types

LinkOut - more resources